Tinkeso Therapeutics develops off-the-shelf, allogeneic Natural Killer T (NKT) cell therapies to treat cancers and autoimmune disorders, with a focus on their lead engineered invariant NKT cell therapy, IMK-101, targeting various leukemia types. The company addresses the rising global incidence of cancer, projected to reach 28 million new cases by 2040, by providing effective cell therapeutic solutions for patients with unmet medical needs.
Funding
Funding not disclosed
Founders
Product
Problem
The rising global incidence of cancer, projected to reach 28 million new cases by 2040, creates a significant unmet need for effective cell therapeutic solutions. Current treatment options may be insufficient for patients with certain cancers and autoimmune disorders.
Solution
Tinkeso Therapeutics is developing off-the-shelf, allogeneic Natural Killer T (NKT) cell therapies to address cancers and autoimmune disorders. Their lead asset, IMK-101, is an engineered invariant NKT (iNKT) cell therapy specifically targeting various types of leukemia. These therapies aim to provide readily available and effective treatment options for patients with unmet medical needs.
Target Audience
The primary target audience includes patients with cancers and autoimmune disorders, particularly those with leukemia, who are seeking novel and effective treatment options.
Features
- Off-the-shelf, allogeneic NKT cell therapies for immediate patient access.
- Engineered invariant NKT (iNKT) cells for enhanced targeting of cancer cells.
- IMK-101, the lead asset, targets several types of leukemia.